Welcome to our dedicated page for Syndax Pharmaceuticals news (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals stock.
Syndax Pharmaceuticals, Inc. (symbol: SNDX) is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts. Dedicated to the development of combination therapies, the company primarily focuses on innovative treatments for various cancer indications.
Syndax's pipeline is rich with promising drugs aimed at improving the lives of cancer patients. The company's leading candidates include entinostat, an agent that targets both cancer cells and immune regulatory cells, and revumenib, a selective inhibitor of the menin-KMT2A binding interaction. This agent is particularly geared towards addressing acute leukemias such as KMT2A-rearranged (KMT2Ar) and NPM1-mutant acute myeloid leukemia (AML). Another notable product in development is axatilimab, a monoclonal antibody designed to enhance the immune response against tumors through CSF-1R inhibition.
Syndax operates primarily within the United States and has achieved several milestones. Recently, the company completed enrollment in the pivotal AUGMENT-101 trial for revumenib targeting relapsed/refractory mutant nucleophosmin (mNPM1) AML. The trial aims to evaluate revumenib's safety, tolerability, and efficacy, with topline data expected by the end of 2024. Positive results from this trial could support new drug applications in early 2025.
Revumenib has achieved several regulatory designations, including Orphan Drug, Fast Track, and Breakthrough Therapy by the FDA, reflecting its potential to address unmet clinical needs in leukemias. Syndax has also reported encouraging outcomes from its studies, including high response rates and favorable safety profiles in both adult and pediatric populations suffering from acute leukemia.
Financially, Syndax maintains a robust position to advance its clinical programs. The company regularly updates stakeholders through earnings calls and investor presentations, with a recent update scheduled for May 2024. Syndax's progress is further bolstered by strategic partnerships and collaborations that support its mission to innovate and deliver significant value to patients and shareholders alike.
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company focused on cancer therapies, announced an inducement stock option grant for its new President, Dr. Neil Gallagher. Effective April 10, 2023, Dr. Gallagher received an award to purchase 250,000 shares at an exercise price of $19.35, the closing stock price on that date. The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter, contingent on Dr. Gallagher's continued employment. This grant was approved by Syndax's Board of Directors in accordance with NASDAQ Listing Rule 5635(c)(4). Syndax's innovative pipeline includes drugs like revumenib and axatilimab, which are in pivotal trials. Further details can be found on their official website.
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a biopharmaceutical company focused on cancer therapies, announced on April 3, 2023, the granting of inducement awards to six new employees under its 2023 Inducement Plan. These awards total 121,100 shares of common stock, with an exercise price set at $20.91 per share, reflecting the closing stock price on that date. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter, contingent upon the employees’ continued service. Syndax's notable pipeline includes revumenib and axatilimab, both currently in pivotal trials.
Syndax Pharmaceuticals (Nasdaq: SNDX) has appointed Neil Gallagher, M.D., Ph.D., as President and Head of Research and Development, effective April 10, 2023. With over 20 years in oncology drug development, including roles at AbbVie and Novartis, Gallagher aims to enhance the company’s pipeline, notably revumenib and axatilimab, both in pivotal trials. CEO Michael A. Metzger praised Gallagher's experience, particularly in securing drug approvals. The transition follows the prior president's shift to the Board of Directors, indicating a strategy for growth and innovation in targeted oncology.
FAQ
What is the current stock price of Syndax Pharmaceuticals (SNDX)?
What is the market cap of Syndax Pharmaceuticals (SNDX)?
What does Syndax Pharmaceuticals, Inc. specialize in?
What are Syndax's key product candidates?
Where is Syndax Pharmaceuticals located?
What recent milestones has Syndax Pharmaceuticals achieved?
What is the significance of revumenib?
Has revumenib received any special designations?
How does Syndax Pharmaceuticals maintain its financial health?
What upcoming events is Syndax participating in?
Where can I find more information about Syndax's clinical trials?
How can I contact Syndax Pharmaceuticals?
